{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Entospletinib",
  "nciThesaurus": {
    "casRegistry": "1229208-44-9",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "An orally available inhibitor of spleen tyrosine kinase (Syk), with potential antineoplastic activity. Upon oral administration of entospletinib, this agent may inhibit the activity of Syk, which inhibits B-cell receptor (BCR) signaling and leads to an inhibition of tumor cell activation, migration, adhesion and proliferation. Syk, a non-receptor cytoplasmic, BCR-associated tyrosine kinase, is expressed in hematopoietic tissues and is often overexpressed in hematopoeitic malignancies.",
    "fdaUniiCode": "6I3O3W6O3B",
    "identifier": "C105402",
    "preferredName": "Entospletinib",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129825",
      "C1967"
    ],
    "synonyms": [
      "6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine",
      "ENTO",
      "ENTOSPLETINIB",
      "Entospletinib",
      "GS 9973",
      "GS-9973",
      "Imidazo(1,2-a)pyrazin-8-amine, 6-(1H-indazol-6-yl)-N-(4-(4-morpholinyl)phenyl)-"
    ]
  }
}